No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IART Integra Lifesciences
- 28.410
- -0.970-3.30%
Close Apr 25 16:00 ET
2.23BMarket Cap33.82P/E (TTM)
29.270High27.180Low1.58MVolume29.270Open29.380Pre Close44.18MTurnover2.34%Turnover Ratio33.82P/E (Static)78.60MShares56.21052wk High1.41P/B1.92BFloat Cap27.18052wk Low--Dividend TTM67.55MShs Float77.400Historical High--Div YieldTTM7.11%Amplitude1.500Historical Low27.944Avg Price1Lot Size
Pre-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Jefferies Sticks to Their Buy Rating for Integra Lifesciences (IART)
Express News | Integra LifeSciences Shares Are Trading Lower. The Company Announced It Will Reschedule Its Q1 Financial Results Conference Call
Integra LifeSciences to Reschedule the First Quarter 2024 Financial Results Conference Call to May 6, 2024
PRINCETON, N.J., April 18, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it has rescheduled the release of the
Earnings Preview: Integra LifeSciences (IART) Q1 Earnings Expected to Decline
Express News | Integra Lifesciences Holdings Corp : Truist Securities Cuts Target Price to $37 From $41
Here's Why Investors Should Retain Integra (IART) Stock Now
Comments
EPS growth doesn't align with share price, indicating it may not reflect business performance or growth expectations may have been high. Integra LifeSciences Holdings' performance led to a 3% annual loss for shareholders over five years. Investors should note 3 warning signs.
While Shareholders of Integra LifeSciences Holdings (NASDAQ:IART) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually GrownInsider transactions suggest a positive outlook for Integra LifeSciences Holdings, with insiders net buying the stock. The level of insider ownership indicates a reasonable degree of alignment with shareholder interests.
1
Integra LifeSciences Holdings trades at a low price, suggesting a buying opportunity. Higher cash flow is expected, potentially boosting share valuation. The positive outlook seems not fully factored into the share price, indicating it's not too late to buy IART.
Analysts insist that Integra LifeSciences' robust future growth justifies its high P/E, negating any expectations of a significant share price drop due to low odds of earnings deterioration.
The Acclarent acquisition provides Integra LifeSciences the chance to scale and seize leadership in the ENT device segment, enriching its innovative portfolio and providing shareholder value. In tandem with Integra's neurosurgery segment, it signifies a strategic move that will enhance innovation across ENT and other CSS technologies.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
